Hosted on MSN1mon
Castle Biosciences (CSTL) Upgraded to Buy: Here's WhyCastle Biosciences, Inc. (CSTL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Castle Biosciences Inc (NASDAQ:CSTL) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $81.91 million, and the earnings are expected to come in at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results